| Year |
Citation |
Score |
| 2022 |
Deng O, Dash S, Nepomuceno TC, Fang B, Yun SY, Welsh EA, Lawrence HR, Marchion D, Koomen JM, Monteiro AN, Rix U. Integrated proteomics identifies PARP inhibitor-induced pro-survival signaling changes as potential vulnerabilities in ovarian cancer. The Journal of Biological Chemistry. 102550. PMID 36183837 DOI: 10.1016/j.jbc.2022.102550 |
0.317 |
|
| 2022 |
Majumder A, Hosseinian S, Stroud M, Adhikari E, Saller JJ, Smith MA, Zhang G, Agarwal S, Creixell M, Meyer BS, Kinose F, Bowers K, Fang B, Stewart PA, Welsh EA, ... ... Koomen JM, et al. Integrated proteomics-based physical and functional mapping of AXL kinase signaling pathways and inhibitors define its role in cell migration. Molecular Cancer Research : McR. PMID 35022314 DOI: 10.1158/1541-7786.MCR-21-0275 |
0.346 |
|
| 2020 |
Zhang C, Smalley I, Emmons MF, Sharma R, Izumi V, Messina J, Koomen JM, Pasquale EB, Forsyth PA, Smalley KSM. Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma. The Journal of Investigative Dermatology. PMID 32890629 DOI: 10.1016/J.Jid.2020.08.012 |
0.377 |
|
| 2020 |
Fang B, Izumi V, Rix LLR, Welsh E, Pike I, Reuther GW, Haura EB, Rix U, Koomen JM. Lowering Sample Requirements to Study Tyrosine Kinase Signaling using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. e2000116. PMID 32865326 DOI: 10.1002/Pmic.202000116 |
0.387 |
|
| 2020 |
Hamaidi I, Zhang L, Kim N, Wang MH, Iclozan C, Fang B, Liu M, Koomen JM, Berglund AE, Yoder SJ, Yao J, Engelman RW, Creelan BC, Conejo-Garcia JR, Antonia SJ, et al. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. Cell Metabolism. PMID 32768387 DOI: 10.1016/J.Cmet.2020.07.008 |
0.31 |
|
| 2020 |
Davis AJ, Tsinkevich M, Rodencal J, Abbas HA, Su XH, Gi YJ, Fang B, Rajapakshe K, Coarfa C, Gunaratne PH, Koomen JM, Tsai KY, Flores ER. TAp63-regulated microRNAs suppress cutaneous squamous cell carcinoma through inhibition of a network of cell cycle genes. Cancer Research. PMID 32156775 DOI: 10.1158/0008-5472.Can-19-1892 |
0.313 |
|
| 2020 |
Smalley I, Law V, Wyatt C, Evernden B, Fang B, Koomen JM, Welsh EA, Macaulay RJB, Forsyth PA, Smalley KSM. Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31924735 DOI: 10.1158/1078-0432.Ccr-19-2840 |
0.305 |
|
| 2020 |
Mooradian M, Cleary JM, Cohen JV, Lawrence DP, Buchbinder EI, Giobbie-Hurder A, Parikh AR, Shapiro G, Darville L, Smalley K, Koomen JM, Newton A, Keer HN, Ivy SP, Chen HX, et al. CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors. Journal of Clinical Oncology. 38: 3609-3609. DOI: 10.1200/Jco.2020.38.15_Suppl.3609 |
0.317 |
|
| 2020 |
Snyder K, Ren H, Lester D, Fang B, Koomen J, H EL. Abstract P2-04-03: The roles of fucosylation in promoting tumorigenic signaling in breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-04-03 |
0.376 |
|
| 2020 |
Creelan B, Wang C, Teer J, Toloza E, Mullinax J, Yao J, Koomen J, Kim S, Chiappori A, Saller J, Montoya L, Landin AM, Tanvetyanon T, Fang B, Thompson Z, et al. Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct056 |
0.321 |
|
| 2020 |
Remsing Rix L, Sumi N, Bryant A, Desai B, Li X, Welsh E, Fang B, Kuenzi B, Antonia S, Lovly C, Koomen J, Marusyk A, Haura E, Rix U. B40 IGF-Binding Protein-Mediated Sensitization of EGFR-Mutant NSCLC Cells to Osimertinib by Cancer-Associated Fibroblast Journal of Thoracic Oncology. 15: S38. DOI: 10.1016/J.Jtho.2019.12.104 |
0.347 |
|
| 2019 |
Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, ... ... Koomen JM, et al. HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms. Blood. PMID 31750881 DOI: 10.1182/Blood.2019895326 |
0.35 |
|
| 2019 |
Lin S, Huang C, Sun J, Bollt O, Wang X, Martine E, Kang J, Taylor MD, Fang B, Singh PK, Koomen J, Hao J, Yang S. The mitochondrial deoxyguanosine kinase is required for cancer cell stemness in lung adenocarcinoma. Embo Molecular Medicine. e10849. PMID 31633874 DOI: 10.15252/Emmm.201910849 |
0.334 |
|
| 2019 |
Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Fellows KM, ... ... Koomen JM, et al. Proteogenomic landscape of squamous cell lung cancer. Nature Communications. 10: 3578. PMID 31395880 DOI: 10.1038/S41467-019-11452-X |
0.36 |
|
| 2019 |
Sumi NJ, Ctortecka C, Hu Q, Bryant AT, Fang B, Remsing Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chemical Biology. PMID 31257184 DOI: 10.1016/J.Chembiol.2019.06.003 |
0.381 |
|
| 2019 |
Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM. HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31227503 DOI: 10.1158/1078-0432.Ccr-18-3382 |
0.32 |
|
| 2019 |
Li Q, Fisher K, Meng W, Fang B, Welsh E, Haura EB, Koomen JM, Eschrich SA, Fridley BL, Chen YA. GMSimpute: a generalized two-step Lasso approach to impute missing values in label-free mass spectrum analysis. Bioinformatics (Oxford, England). PMID 31199438 DOI: 10.1093/Bioinformatics/Btz488 |
0.302 |
|
| 2019 |
Koomen DC, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meads MB, Nguyen T, Meke L, Eschrich SA, Shain KH, Garrett TJ, Koomen JM. Proteometabolomics of Melphalan Resistance in Multiple Myeloma. Methods in Molecular Biology (Clifton, N.J.). 1996: 273-296. PMID 31127562 DOI: 10.1182/Blood-2018-99-117747 |
0.321 |
|
| 2019 |
Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, ... Koomen JM, et al. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 35: 752-766.e9. PMID 31085176 DOI: 10.1016/J.Ccell.2019.04.005 |
0.322 |
|
| 2019 |
Yin Q, Han T, Fang B, Zhang G, Zhang C, Roberts ER, Izumi V, Zheng M, Jiang S, Yin X, Kim M, Cai J, Haura EB, Koomen JM, Smalley KSM, et al. K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. Nature Communications. 10: 1870. PMID 31015455 DOI: 10.1038/S41467-019-09844-0 |
0.35 |
|
| 2019 |
Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, Chen YA, Lau EK, Wan L, Licht JD, Smalley KSM. HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. Cancer Research. PMID 30987999 DOI: 10.1158/0008-5472.Can-19-0040 |
0.369 |
|
| 2019 |
Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pabón-Saldaña M, Darville L, Fang B, Rix U, Yoder S, Berglund A, Koomen JM, Haura EB, Abate-Daga D. An immunoproteomic approach to characterize the CAR interactome and signalosome. Science Signaling. 12. PMID 30755478 DOI: 10.1126/Scisignal.Aap9777 |
0.336 |
|
| 2019 |
Koomen DC, Meads MB, Magaletti DM, Guingab JD, Oliveira PS, Fang B, Izumi V, Renatino-Canevarolo R, Sudalagunta PR, Silva M, Alugubelli R, De Avilla G, Tungeskiv A, Welsh EA, Meke LE, ... ... Koomen JM, et al. Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma Blood. 134: 5534-5534. DOI: 10.1182/Blood-2019-132001 |
0.356 |
|
| 2019 |
Burger KL, Meads MB, Berglund A, Oliveira PS, Distler A, Sudalagunta PR, Jacobson T, Teer J, Welsh EA, Dai H, Koomen JM, Raghunandan Reddy A, De Avila G, Tungesvik A, Roush W, et al. A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma Blood. 134: 5537-5537. DOI: 10.1182/Blood-2019-130830 |
0.369 |
|
| 2019 |
Sharma V, Yue L, Horvat NP, Christodoulidou A, Akuffo AA, Beatty M, Murdun C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville L, ... ... Koomen JM, et al. Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms Blood. 134: 474-474. DOI: 10.1182/Blood-2019-127235 |
0.366 |
|
| 2019 |
Faiao-Flores F, Emmons M, Durante M, Saha B, Fang B, Koomen J, Chellappan S, Maria-Engler S, Licht J, Harbour W, Smalley K. Abstract 378: HDAC inhibition enhances MEK antagonist therapy in uveal melanoma through combined blockade of YAP, AKT and RTK signaling Cancer Research. 79: 378-378. DOI: 10.1158/1538-7445.Sabcs18-378 |
0.39 |
|
| 2019 |
Lin S, Huang C, Sun J, Wang X, Kang J, Taylor M, Fang B, Singh PK, Koomen J, Hao J, Yang S. Abstract 973: The mitochondrial deoxyguanosine kinase regulates lung adenocarcinoma cancer stem-like cells through AMPK/YAP1 signaling Cancer Research. 79: 973-973. DOI: 10.1158/1538-7445.Am2019-973 |
0.359 |
|
| 2019 |
Majumder A, Zhang G, Adhikari E, Fang B, Welsh EA, Koomen JM, Haura EB. Abstract 4543: Proteomic characterization of AXL kinase inhibitors and signaling pathways Cancer Research. 79: 4543-4543. DOI: 10.1158/1538-7445.Am2019-4543 |
0.44 |
|
| 2019 |
Rix LLR, Sumi NJ, Bryant AT, Li X, Welsh EA, Fang B, Kuenzi BM, Antonia SJ, Marusyk A, Lovly CM, Koomen JM, Haura EB, Rix U. Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C110 |
0.433 |
|
| 2019 |
Zhang G, Ross K, Akcora C, Smirnova K, Fang B, Koomen JM, Haura EB, Grimes M. Abstract B025: Integrative omics analysis decodes cross-talk between signaling pathways to understand the anti-cancer mechanism of TKIs in NSCLC Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B025 |
0.396 |
|
| 2019 |
Palve V, Knezevic C, Luo Y, Li X, Novakova S, Welsh E, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Lawrence HR, Rix U. Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B021 |
0.407 |
|
| 2018 |
Pérez-Morales J, Mejías-Morales D, Rivera-Rivera S, González-Flores J, González-Loperena M, Cordero-Báez FY, Pedreira-García WM, Chardón-Colón C, Cabán-Rivera J, Cress WD, Gordian ER, Muñoz-Antonia T, Cabrera-Ríos M, Isidro A, Coppola D, ... ... Koomen JM, et al. Hyper-phosphorylation of Rb S249 together with CDK5R2/p39 overexpression are associated with impaired cell adhesion and epithelial-to-mesenchymal transition: Implications as a potential lung cancer grading and staging biomarker. Plos One. 13: e0207483. PMID 30452490 DOI: 10.1371/Journal.Pone.0207483 |
0.339 |
|
| 2018 |
Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, Ren Y, Fang B, Yoder S, Kim S, Wan L, Sarnaik AA, Koomen JM, Messina JL, Teer JK, et al. PTPN11 plays oncogenic roles and is a therapeutic target for BRAF wild-type melanomas. Molecular Cancer Research : McR. PMID 30355677 DOI: 10.1158/1541-7786.Mcr-18-0777 |
0.373 |
|
| 2018 |
Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham L, Sudalagunta PR, et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. The Journal of Clinical Investigation. PMID 30260324 DOI: 10.1172/Jci122533 |
0.37 |
|
| 2018 |
Ctortecka C, Palve V, Kuenzi BM, Fang B, Sumi NJ, Izumi V, Novakova S, Kinose F, Remsing Rix LL, Haura EB, Koomen JM, Rix U. Functional proteomics and deep network interrogation reveal a complex mechanism of action of midostaurin in lung cancer cells. Molecular & Cellular Proteomics : McP. PMID 30217950 DOI: 10.1074/Mcp.Ra118.000713 |
0.42 |
|
| 2018 |
Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, ... ... Koomen JM, et al. Combined BRAF and HSP90 inhibition in patients with unresectable V600E mutant melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29674508 DOI: 10.1158/1078-0432.Ccr-18-0565 |
0.314 |
|
| 2018 |
Guo D, Xu Q, Pabla S, Koomen J, Biddinger P, Sharma A, Pabla S, Pacholczyk R, Chang CC, Friedrich K, Mohammed K, Smallridge RC, Copland JA, She JX, Weinberger PM. Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein. International Journal of Molecular Sciences. 19. PMID 29443941 DOI: 10.3390/Ijms19020577 |
0.366 |
|
| 2018 |
Meads MB, Renatino Canevarolo R, Sudalagunta PR, Oliveira PS, Magaletti DM, Fang B, Coelho Siqueira Silva MD, Kulkarni A, Dai H, Dalton WS, Petre I, Koomen JM, Siqueira Silva A, Shain KH. Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma Blood. 132: 950-950. DOI: 10.1182/Blood-2018-99-120269 |
0.419 |
|
| 2018 |
Ren Y, Bi C, Zhao X, Lwin T, Cheng W, Yuan J, Siqueira Silva A, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham LV, Sudalagunta PR, et al. Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas Blood. 132: 2853-2853. DOI: 10.1182/Blood-2018-99-118004 |
0.377 |
|
| 2018 |
Djidjou MB, Kim J, Han K, Wright G, Majumder A, Fang B, Koomen J, Rix LLR, Rix U, Haura E. Abstract 5089: A quantitative proteomic survey reveals mechanisms of the bi-directional signaling between lung fibroblasts and lung cancer cells Cancer Research. 78: 5089-5089. DOI: 10.1158/1538-7445.Am2018-5089 |
0.451 |
|
| 2018 |
Zhang C, Smalley I, Sharma R, Emmons M, Messina J, Koomen J, Smalley K. Abstract 3025: Ligand-independent EphA2 signaling drives an amoeboid phenotype that promotes melanoma brain metastasis development Cancer Research. 78: 3025-3025. DOI: 10.1158/1538-7445.Am2018-3025 |
0.374 |
|
| 2018 |
Welsh EA, Stewart PA, Chambers MC, Zhang G, Fang B, Eschrich SA, Koomen JM, Haura EB. Abstract 2708: Imputation-free analysis of high throughput TMT proteomics of 116 lung squamous samples Cancer Research. 78: 2708-2708. DOI: 10.1158/1538-7445.Am2018-2708 |
0.36 |
|
| 2018 |
Zhang G, Ross K, Fang B, Zhou J, Stewart PA, Adhikari E, Welsh EA, Wang X, Koomen JM, Wu CH, Haura EB. Abstract 1308: Post translational crosstalk networks identify strategies to overcome EMT-mediated resistance to EGFR inhibitors Cancer Research. 78: 1308-1308. DOI: 10.1158/1538-7445.Am2018-1308 |
0.42 |
|
| 2017 |
Chen Y, Britton D, Wood ER, Brantley S, Fournier M, Wloch M, Williams VL, Johnson J, Magliocco A, Pike I, Koomen JM. Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors. Methods in Molecular Biology (Clifton, N.J.). PMID 29243084 DOI: 10.1007/7651_2017_113 |
0.367 |
|
| 2017 |
Hoffman MA, Fang B, Haura EB, Rix U, Koomen JM. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. Journal of Proteome Research. PMID 29164889 DOI: 10.1021/Acs.Jproteome.7B00329 |
0.421 |
|
| 2017 |
Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nature Chemical Biology. PMID 28991240 DOI: 10.1038/Nchembio.2489 |
0.417 |
|
| 2017 |
Chen S, Fisher RC, Signs S, Molina LA, Shenoy AK, Lopez MC, Baker HV, Koomen JM, Chen Y, Gittleman H, Barnholtz-Sloan J, Berg A, Appelman HD, Huang EH. Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. Oncotarget. 8: 50476-50488. PMID 28881576 DOI: 10.18632/Oncotarget.9919 |
0.381 |
|
| 2017 |
Chen Y, Fisher KJ, Lloyd M, Wood ER, Coppola D, Siegel E, Shibata D, Chen YA, Koomen JM. Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins. Methods in Molecular Biology (Clifton, N.J.). 1647: 19-45. PMID 28808993 DOI: 10.1007/978-1-4939-7201-2_2 |
0.432 |
|
| 2017 |
Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, ... ... Koomen JM, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nature Communications. 8: 14920. PMID 28416797 DOI: 10.1038/Ncomms14920 |
0.373 |
|
| 2017 |
Frieling JS, Shay G, Izumi V, Aherne ST, Saul RG, Budzevich M, Koomen J, Lynch CC. Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP1-17. Oncogene. PMID 28368420 DOI: 10.1038/Onc.2017.70 |
0.304 |
|
| 2017 |
Stewart PA, Fang B, Slebos RJ, Zhang G, Borne AL, Fellows K, Teer JK, Chen YA, Welsh E, Eschrich SA, Haura EB, Koomen JM. Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms. Proteomics. PMID 28195392 DOI: 10.1002/Pmic.201600300 |
0.38 |
|
| 2017 |
Chen Y, Britton D, Wood ER, Brantley S, Magliocco A, Pike I, Koomen JM. Quantitative proteomics of breast tumors: Tissue quality assessment to clinical biomarkers. Proteomics. PMID 28127872 DOI: 10.1002/Pmic.201600335 |
0.372 |
|
| 2017 |
Meads MB, Oliveira P, Fang B, Sudalagunta P, Silva MDCS, Nguyen T, Distler A, Komrokji S, Collins A, Dai H, Koomen JM, Silva AS, Shain KH. Identification of Target Pathways of Acquired IMiD and Proteasome Inhibitor Resistance in Multiple Myeloma Blood. 130: 4411-4411. DOI: 10.1182/Blood.V130.Suppl_1.4411.4411 |
0.431 |
|
| 2017 |
Sumi NJ, Fang B, Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Abstract 221: Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC Cancer Research. 77: 221-221. DOI: 10.1158/1538-7445.Am2017-221 |
0.43 |
|
| 2017 |
Stewart PA, Slebos RJ, Welsh EA, Cen L, Zhang Y, Chen Z, Cheng C, Pettersson F, Berglund A, Zhang G, Fang B, Izumi V, Yoder S, Fellows K, Chen A, ... ... Koomen JM, et al. Abstract 205: Underlying mechanisms of genome-proteome discordance in squamous cell lung cancer Cancer Research. 77: 205-205. DOI: 10.1158/1538-7445.Am2017-205 |
0.311 |
|
| 2017 |
Pettersson F, Stewart PA, Slebos RJ, Welsh EA, Cen L, Zhang Y, Chen Z, Cheng C, Zhang G, Fang B, Izumi V, Yoder S, Fellows K, Chen YA, Teer JK, ... ... Koomen JM, et al. Abstract 1565: OnPLS-based integrative proteogenomics analysis of lung squamous cell cancer Cancer Research. 77: 1565-1565. DOI: 10.1158/1538-7445.Am2017-1565 |
0.319 |
|
| 2016 |
Kim JY, Stewart PA, Borne AL, Fang B, Welsh EA, Chen YA, Eschrich SA, Koomen JM, Haura EB. Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. Proteomes. 4: 16. PMID 28154798 DOI: 10.3390/Proteomes4020016 |
0.406 |
|
| 2016 |
Sharma R, Fedorenko I, Spence PT, Sondak VK, Smalley KS, Koomen JM. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. Journal of Proteome Research. 15: 4476-4489. PMID 27934295 DOI: 10.1021/Acs.Jproteome.6B00613 |
0.399 |
|
| 2016 |
Knezevic CE, Wright G, Remsing Rix LL, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chemical Biology. PMID 27866910 DOI: 10.1016/J.Chembiol.2016.10.011 |
0.36 |
|
| 2016 |
Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ. IKKϵ phosphorylation of estrogen receptor α Ser-167 and contribution to tamoxifen resistance in breast cancer. The Journal of Biological Chemistry. 291: 22857. PMID 27825095 DOI: 10.1074/Jbc.A109.078212 |
0.349 |
|
| 2016 |
Zhang G, Scarborough H, Kim J, Rozhok AI, Chen YA, Zhang X, Song L, Bai Y, Fang B, Liu RZ, Koomen J, Tan AC, Degregori J, Haura EB. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. Science Signaling. 9: rs12. PMID 27811184 DOI: 10.1126/Scisignal.Aaf5011 |
0.421 |
|
| 2016 |
Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, Koomen JM, Haura EB. Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-driven AKT signaling in KRAS-mutant lung cancer. Molecular Cancer Research : McR. PMID 27422710 DOI: 10.1158/1541-7786.Mcr-15-0506 |
0.395 |
|
| 2016 |
Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, Rathmell WK, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27220961 DOI: 10.1158/1078-0432.Ccr-15-1673 |
0.335 |
|
| 2016 |
Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN. PAXIP1 potentiates the combination of WEE1 inhibitor AZD1775 and platinum agents in lung cancer. Molecular Cancer Therapeutics. PMID 27196765 DOI: 10.1158/1535-7163.Mct-15-0182 |
0.396 |
|
| 2016 |
Li J, Fang B, Kinose F, Bai Y, Kim JY, Chen YA, Rix U, Koomen JM, Haura EB. Target identification in small cell lung cancer via integrated phenotypic screening and activity-based protein profiling. Molecular Cancer Therapeutics. PMID 26772203 DOI: 10.1158/1535-7163.Mct-15-0444 |
0.403 |
|
| 2016 |
Eroglu Z, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Tetteh LF, Ramadan H, Zhao X, Chen A, Sharma R, Messina J, Koomen JM, Sondak VK, Smalley K. Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma. Journal of Clinical Oncology. 34: 9544-9544. DOI: 10.1200/Jco.2016.34.15_Suppl.9544 |
0.308 |
|
| 2016 |
Meads MB, Oliveira P, Distler A, Silva M, Burger K, Fang B, Collins A, Cleveland JL, Koomen JM, Silva A, Rebatchouk D, Shain KH, Roush WR. Identification of Target Pathways Induced By the Multiple Myeloma Tumor Microenvironment Using Activity-Based Protein Profiling and Ex Vivo Protein Kinase Inhibitor Screening Blood. 128: 3288-3288. DOI: 10.1182/Blood.V128.22.3288.3288 |
0.414 |
|
| 2016 |
Peterman S, Fang B, Hoffmann M, Prakash A, Stewart PA, Liu R, Smith M, Johnson J, Eschrich S, Zhang G, Haura E, Koomen J. Abstract LB-140: Scaling discovery proteomics to large lung cancer cohorts using data independent acquisition Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-140 |
0.724 |
|
| 2016 |
Kumar RS, Macaulay RJB, Rutherford HC, Barkey N, Li J, Kim J, Koomen JM, Morse DL. Abstract 3876: EphrinB3 and EphrinB4 receptors: potential therapeutic targets in glioblastoma Cancer Research. 76: 3876-3876. DOI: 10.1158/1538-7445.Am2016-3876 |
0.335 |
|
| 2015 |
Damaghi M, Tafreshi NK, Lloyd MC, Sprung R, Estrella V, Wojtkowiak JW, Morse DL, Koomen JM, Bui MM, Gatenby RA, Gillies RJ. Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane. Nature Communications. 6: 8752. PMID 26658462 DOI: 10.1038/Ncomms9752 |
0.307 |
|
| 2015 |
Stewart PA, Parapatics K, Welsh EA, Müller AC, Cao H, Fang B, Koomen JM, Eschrich SA, Bennett KL, Haura EB. A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma. Plos One. 10: e0142162. PMID 26539827 DOI: 10.1371/Journal.Pone.0142162 |
0.328 |
|
| 2015 |
Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH. Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. PMID 26387544 DOI: 10.1038/Onc.2015.334 |
0.39 |
|
| 2015 |
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. PMID 26073081 DOI: 10.1038/Onc.2015.188 |
0.404 |
|
| 2015 |
Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods (San Diego, Calif.). 81: 41-9. PMID 25782629 DOI: 10.1016/J.Ymeth.2015.03.006 |
0.717 |
|
| 2015 |
Schneeberger VE, Ren Y, Luetteke N, Huang Q, Chen L, Lawrence HR, Lawrence NJ, Haura EB, Koomen JM, Coppola D, Wu J. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget. 6: 6191-202. PMID 25730908 DOI: 10.18632/Oncotarget.3356 |
0.326 |
|
| 2015 |
Peng L, Yuan Z, Li Y, Ling H, Izumi V, Fang B, Fukasawa K, Koomen J, Chen J, Seto E. Ubiquitinated sirtuin 1 (SIRT1) function is modulated during DNA damage-induced cell death and survival. The Journal of Biological Chemistry. 290: 8904-12. PMID 25670865 DOI: 10.1074/Jbc.M114.612796 |
0.303 |
|
| 2015 |
Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discovery. 5: 264-73. PMID 25542447 DOI: 10.1158/2159-8290.Cd-14-0293 |
0.342 |
|
| 2015 |
Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics. 15: 327-39. PMID 25339196 DOI: 10.1002/Pmic.201400200 |
0.36 |
|
| 2015 |
Fedorenko IV, Paraiso KHT, Fang B, Koomen JM, Smalley KSM. Abstract IA04: Using comprehensive proteomic approaches to map signaling adaptations to BRAF and BRAF/MEK inhibition Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Ia04 |
0.4 |
|
| 2015 |
Sharma R, Phadke M, Britton D, Pike I, Smalley K, Koomen JM. Abstract 2006: Kinases and adaptive signaling contribute to drug resistance in BRAF mutant melanoma Cancer Research. 75: 2006-2006. DOI: 10.1158/1538-7445.Am2015-2006 |
0.311 |
|
| 2015 |
Kuhn E, Whiteaker JR, Martinez M, Holderfield M, Kennedy J, Jaffe J, Yan P, Lin C, Whiteley G, Carr SA, Paulovich AG, Koomen JM. Abstract 2002: Assembling test points for quantitative proteomics to elucidate RAS signaling Cancer Research. 75: 2002-2002. DOI: 10.1158/1538-7445.Am2015-2002 |
0.382 |
|
| 2015 |
Martinez M, Fang B, Li J, Chen YA, Brantley S, Guan W, Kinose F, Welsh E, Eschrich SA, Haura EB, Koomen JM. Abstract 1817: Quantitative proteomics identifies unique signaling phenotypes in NSCLC Cancer Research. 75: 1817-1817. DOI: 10.1158/1538-7445.Am2015-1817 |
0.445 |
|
| 2015 |
Damaghi M, Sprung R, Tafreshi N, Estrella V, Koomen J, Morse D, Gillies R. Abstract 1265: LAMP2 overexpression in the plasma membrane of breast cancer cells in response of chronic acidosis as a new imaging and therapeutic target Cancer Research. 75: 1265-1265. DOI: 10.1158/1538-7445.Am2015-1265 |
0.329 |
|
| 2015 |
Sharma R, Fedorenko I, Koncarevic S, Mitra V, Selzer S, Boehm G, Pike I, Smalley K, Koomen JM. Abstract LB-C12: Functional proteomics elucidates signaling adaptation driven by combination therapy in BRAF mutant melanoma cell line models Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-C12 |
0.444 |
|
| 2014 |
Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, Rix U, Haura EB. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Research. 74: 7217-28. PMID 25348954 DOI: 10.1158/0008-5472.Can-14-0505 |
0.418 |
|
| 2014 |
Fedorenko IV, Fang B, Koomen JM, Gibney GT, Smalley KS. Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Research. 24: 448-53. PMID 24950457 DOI: 10.1097/Cmr.0000000000000103 |
0.358 |
|
| 2014 |
Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen AY, Kitano M, Morita Y, Yamaguchi H, Shibata K, et al. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4059-74. PMID 24919575 DOI: 10.1158/1078-0432.Ccr-13-1559 |
0.354 |
|
| 2014 |
Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Molecular & Cellular Proteomics : McP. 13: 1844-54. PMID 24760959 DOI: 10.1074/Mcp.M113.037424 |
0.442 |
|
| 2014 |
Remily-Wood ER, Benson K, Baz RC, Chen YA, Hussein M, Hartley-Brown MA, Sprung RW, Perez B, Liu RZ, Yoder SJ, Teer JK, Eschrich SA, Koomen JM. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients. Proteomics. Clinical Applications. 8: 783-95. PMID 24723328 DOI: 10.1002/Prca.201300077 |
0.312 |
|
| 2014 |
Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW, Grant RP, Hoofnagle AN, Hüttenhain R, Koomen JM, Liebler DC, Liu T, MacLean B, Mani DR, Mansfield E, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Molecular & Cellular Proteomics : McP. 13: 907-17. PMID 24443746 DOI: 10.1074/Mcp.M113.036095 |
0.347 |
|
| 2014 |
Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, Li J, Koomen JM, Haura EB, Lawrence HR, Rix U. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells Acs Chemical Biology. 9: 353-358. PMID 24215125 DOI: 10.1021/Cb400660A |
0.403 |
|
| 2014 |
Chen Y, Britton DJ, Wood ER, Han HS, Magliocco AM, Pike I, Koomen JM. Liquid chromatography-multiple reaction monitoring mass spectrometry biomarker quantification for breast cancer patient assessment. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E22219 |
0.345 |
|
| 2014 |
Shain KH, Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Ring JE, MacLeod R, Hazlehurst L, Lynch C, Pachter JA, Matsui W, Koomen J, Nguyen T. Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death Blood. 124: 2081-2081. DOI: 10.1182/Blood.V124.21.2081.2081 |
0.394 |
|
| 2014 |
Kim J, Fang B, Welsh EA, Kinose F, Li J, Eschrich SA, Koomen JM, Haura EB. Abstract A31: Activity-based protein profiling reveals adaptive response to pharmacological MEK inhibition in KRAS mutant non-small cell lung cancer Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A31 |
0.438 |
|
| 2014 |
Haake SM, Li J, Bai Y, Fang B, Pow-Sang J, Koomen J, Fishman M, Haura EB. Abstract 5305: Phosphoproteomics analysis reveals differential signaling pathways among clear cell and papillary renal cell carcinoma tumors Cancer Research. 74: 5305-5305. DOI: 10.1158/1538-7445.Am2014-5305 |
0.428 |
|
| 2014 |
Meads MB, Fang B, Mathews L, Gemmer J, Nong L, MacCleod R, Hazlehurst L, Koomen J, Shain KH. Abstract 4892: PYK2 mediates microenvironment-specific myeloma survival Cancer Research. 74: 4892-4892. DOI: 10.1158/1538-7445.Am2014-4892 |
0.373 |
|
| 2014 |
Chen Y, Britton DJ, Paraiso K, Fedorenko I, Wood ER, Magliocco A, Sondak VK, Smalley K, Pike I, Koomen JM. Abstract 2491: Quantification of biomarker expression, phosphorylation, and mutation in cancer using TMT labeling prior to liquid chromatography-multiple reaction monitoring mass spectrometry Cancer Research. 74: 2491-2491. DOI: 10.1158/1538-7445.Am2014-2491 |
0.401 |
|
| 2014 |
Fang B, Wood ER, Li J, Chen YA, Brantley SG, Kinose F, Guan W, Myers AR, Eschrich SA, Haura EB, Koomen JM. Abstract 1614: Kinases in lung squamous cell carcinoma and inhibitor matching using quantitative activity-based protein profiling Cancer Research. 74: 1614-1614. DOI: 10.1158/1538-7445.Am2014-1614 |
0.434 |
|
| 2014 |
Paraiso KHT, Thakur MD, John JK, Fang B, Koomen JM, Fedorenko IV, Tsao H, Flaherty KT, Messina JL, Pasquale EM, Villagra A, Kirkwood JM, Meier F, Sloot S, Gibney GT, et al. Abstract 1610: MAPK inhibitor resistance leads to ligand-independent Ephrin A2 receptor signaling and the formation of new melanoma metastases Cancer Research. 74: 1610-1610. DOI: 10.1158/1538-7445.Am2014-1610 |
0.388 |
|
| 2013 |
Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, ... ... Koomen J, et al. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Molecular Systems Biology. 9: 705. PMID 24189400 DOI: 10.1038/Msb.2013.61 |
0.372 |
|
| 2013 |
He G, Kuang J, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents. British Journal of Cancer. 109: 2378-88. PMID 24104967 DOI: 10.1038/Bjc.2013.613 |
0.316 |
|
| 2013 |
Williams KA, Zhang M, Xiang S, Hu C, Wu JY, Zhang S, Ryan M, Cox AD, Der CJ, Fang B, Koomen J, Haura E, Bepler G, Nicosia SV, Matthias P, et al. Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. The Journal of Biological Chemistry. 288: 33156-70. PMID 24089523 DOI: 10.1074/Jbc.M113.472506 |
0.358 |
|
| 2013 |
Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Molecular Cancer Therapeutics. 12: 2446-58. PMID 24048737 DOI: 10.1158/1535-7163.Mct-13-0310 |
0.343 |
|
| 2013 |
Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 110: 12414-9. PMID 23836654 DOI: 10.1073/Pnas.1220674110 |
0.414 |
|
| 2013 |
Song T, Yang L, Kabra N, Chen L, Koomen J, Haura EB, Chen J. The NAD+ synthesis enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT1) regulates ribosomal RNA transcription. The Journal of Biological Chemistry. 288: 20908-17. PMID 23737528 DOI: 10.1074/Jbc.M113.470302 |
0.323 |
|
| 2013 |
Martyniuk CJ, Feswick A, Fang B, Koomen JM, Barber DS, Gavin T, Lopachin RM. Protein targets of acrylamide adduct formation in cultured rat dopaminergic cells. Toxicology Letters. 219: 279-87. PMID 23566896 DOI: 10.1016/J.Toxlet.2013.03.031 |
0.363 |
|
| 2013 |
Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak VK, Koomen JM, Smalley KS. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Molecular Cancer Therapeutics. 12: 901-12. PMID 23538902 DOI: 10.1158/1535-7163.Mct-12-1003 |
0.379 |
|
| 2013 |
Meads M, Fang B, Mathews L, Gemmer J, Nong L, Hazlehurst LA, MacLeod R, Koomen J, Shain K. PYK2 Mediates Microenvironment-Specific Myeloma Survival Blood. 122: 4443-4443. DOI: 10.1182/Blood.V122.21.4443.4443 |
0.381 |
|
| 2013 |
Kim J, Welsh EA, Fang B, Oguz U, Li J, Kinose F, Bronk C, Beg AA, Chen A, Eschrich S, Koomen J, Haura EB. Abstract 937: Dissection of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer cells. Cancer Research. 73: 937-937. DOI: 10.1158/1538-7445.Am2013-937 |
0.436 |
|
| 2013 |
Paraiso KHT, Fang B, Han D, Fedorenko I, John J, Koomen J, Wargo J, Flaherty K, Meier F, Smalley KSM. Abstract 5237: Systems level modeling following BRAF inhibition reveals an essential role for Ephrin A2 receptor in therapeutic escape. Cancer Research. 73: 5237-5237. DOI: 10.1158/1538-7445.Am2013-5237 |
0.4 |
|
| 2013 |
Remily-Wood E, Paraiso K, Haarberg E, Chen YA, Rebecca V, Smalley K, Koomen JM. Abstract 3209: Elucidating drug resistance mechanisms in melanoma with quantitative proteomics. Cancer Research. 73: 3209-3209. DOI: 10.1158/1538-7445.Am2013-3209 |
0.441 |
|
| 2013 |
Chen Y, Britton DJ, Wood ER, Magliocco AM, Pike I, Koomen JM. Abstract 2494: Liquid chromatography-multiple reaction monitoring mass spectrometry biomarker quantification for breast cancer patient assessment. Cancer Research. 73: 2494-2494. DOI: 10.1158/1538-7445.Am2013-2494 |
0.409 |
|
| 2013 |
Fang B, Li J, Chen YA, Eschrich SA, Myers AR, Haura EB, Koomen JM. Abstract 2483: Signaling phenotypes in non-small cell lung cancer and normal lung defined by kinase activity profiling and phosphoproteomics. Cancer Research. 73: 2483-2483. DOI: 10.1158/1538-7445.Am2013-2483 |
0.434 |
|
| 2013 |
Kim J, Welsh EA, Fang B, Li J, Eschrich SA, Koomen J, Haura EB. Abstract A61: Characterization of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A61 |
0.43 |
|
| 2012 |
Woods NT, Mesquita RD, Sweet M, Carvalho MA, Li X, Liu Y, Nguyen H, Thomas CE, Iversen ES, Marsillac S, Karchin R, Koomen J, Monteiro AN. Charting the landscape of tandem BRCT domain-mediated protein interactions. Science Signaling. 5: rs6. PMID 22990118 DOI: 10.1126/Scisignal.2002255 |
0.35 |
|
| 2012 |
John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KS. GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. The Journal of Investigative Dermatology. 132: 2818-27. PMID 22810307 DOI: 10.1038/Jid.2012.237 |
0.354 |
|
| 2012 |
Peng L, Ling H, Yuan Z, Fang B, Bloom G, Fukasawa K, Koomen J, Chen J, Lane WS, Seto E. SIRT1 negatively regulates the activities, functions, and protein levels of hMOF and TIP60. Molecular and Cellular Biology. 32: 2823-36. PMID 22586264 DOI: 10.1128/Mcb.00496-12 |
0.308 |
|
| 2012 |
Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura EB. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Research. 72: 2501-11. PMID 22461510 DOI: 10.1158/0008-5472.Can-11-3015 |
0.371 |
|
| 2012 |
Remily-Wood ER, Koomen JM. Evaluation of protein quantification using standard peptides containing single conservative amino acid replacements. Journal of Mass Spectrometry : Jms. 47: 188-94. PMID 22359328 DOI: 10.1002/Jms.2053 |
0.337 |
|
| 2012 |
Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2502-14. PMID 22351686 DOI: 10.1158/1078-0432.Ccr-11-2612 |
0.301 |
|
| 2012 |
Xiang Y, Koomen JM. Evaluation of direct infusion-multiple reaction monitoring mass spectrometry for quantification of heat shock proteins. Analytical Chemistry. 84: 1981-6. PMID 22293045 DOI: 10.1021/Ac203011J |
0.379 |
|
| 2012 |
An Z, Chen Y, Koomen JM, Merkler DJ. A mass spectrometry-based method to screen for α-amidated peptides. Proteomics. 12: 173-82. PMID 22106059 DOI: 10.1002/Pmic.201100327 |
0.31 |
|
| 2012 |
Gebhard AW, Nair RR, Emmons M, Jain PR, Becker A, Koomen J, Schonbrunn E, Sullivan DM, McLaughlin ML, Hazlehurst LA. Mti-101 (cyclized HYD1) Binds to CD44 and Induces Necrotic Cell Death in Multiple Myeloma Blood. 120: 4022-4022. DOI: 10.1182/Blood.V120.21.4022.4022 |
0.334 |
|
| 2012 |
Fedorenko IV, Paraiso KHT, Rebecca VW, Wood E, Koomen J, Messina J, Smalley K. Abstract 5222: A novel mechanism of microenvironment-mediated drug resistance in BRAF V600E melanoma with loss of PTEN Cancer Research. 72: 5222-5222. DOI: 10.1158/1538-7445.Am2012-5222 |
0.417 |
|
| 2012 |
Chen Y, Britton DJ, Wood ER, Pike I, Koomen JM. Abstract 4810: Multiplexed immunoprecipitation-liquid chromatography-multiple reaction monitoring mass spectrometry quantification of protein expression and phosphorylation for breast cancer biomarkers Cancer Research. 72: 4810-4810. DOI: 10.1158/1538-7445.Am2012-4810 |
0.419 |
|
| 2012 |
Fang B, Xiang Y, Mirza S, Remily-Wood E, Mathews L, Dalton W, Shain K, Koomen JM. Abstract 4809: Elucidating acquired drug resistance in multiple myeloma using expression proteomics and phosphorylation profiling Cancer Research. 72: 4809-4809. DOI: 10.1158/1538-7445.Am2012-4809 |
0.432 |
|
| 2012 |
Haura EB, Yoshida T, Fang B, Stukalov A, Eschrich S, Welsh E, Colinge J, Koomen J, Superti-Furga G, Li J, Rix U, Zhang G, Kim J, Bennett K, Song L, et al. Abstract IA2: Network models in oncogene-addicted lung cancer Clinical Cancer Research. 18: IA2-IA2. DOI: 10.1158/1078-0432.12Aacriaslc-Ia2 |
0.43 |
|
| 2011 |
Martyniuk CJ, Fang B, Koomen JM, Gavin T, Zhang L, Barber DS, Lopachin RM. Molecular mechanism of glyceraldehyde-3-phosphate dehydrogenase inactivation by α,β-unsaturated carbonyl derivatives. Chemical Research in Toxicology. 24: 2302-11. PMID 22084934 DOI: 10.1021/Tx200437Y |
0.301 |
|
| 2011 |
Peng L, Yuan Z, Ling H, Fukasawa K, Robertson K, Olashaw N, Koomen J, Chen J, Lane WS, Seto E. SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Molecular and Cellular Biology. 31: 4720-34. PMID 21947282 DOI: 10.1128/Mcb.06147-11 |
0.31 |
|
| 2011 |
Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, ... Koomen JM, et al. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Molecular & Cellular Proteomics : McP. 10: M110.005520. PMID 21846842 DOI: 10.1074/Mcp.M110.005520 |
0.399 |
|
| 2011 |
Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, ... ... Koomen JM, et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics. Clinical Applications. 5: 383-96. PMID 21656910 DOI: 10.1002/Prca.201000115 |
0.42 |
|
| 2011 |
Koomen JM, Smalley KS. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget. 2: 329-35. PMID 21505227 DOI: 10.18632/Oncotarget.263 |
0.411 |
|
| 2011 |
Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Research. 71: 2750-60. PMID 21317224 DOI: 10.1158/0008-5472.Can-10-2954 |
0.383 |
|
| 2011 |
Zhang G, Fang B, Liu RZ, Lin H, Kinose F, Bai Y, Oguz U, Remily-Wood ER, Li J, Altiok S, Eschrich S, Koomen J, Haura EB. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity Journal of Proteome Research. 10: 305-319. PMID 21080693 DOI: 10.1021/Pr1006203 |
0.394 |
|
| 2011 |
Paraiso KH, Rebecca V, Fedorenko IV, Xiang Y, Wood E, Anderson AR, Sondak VK, Abel EV, Koomen JM, Messina JL, Smalley KSM. Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression Cancer Research. 71: 5370-5370. DOI: 10.1158/1538-7445.Am2011-5370 |
0.399 |
|
| 2011 |
He G, Kuang J, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Abstract 5361: DNA damage by platinum-based drugs induces p21-dependent recruitment of PCNA as a homotrimer into the inhibited G1-phase CDK complex Cancer Research. 71: 5361-5361. DOI: 10.1158/1538-7445.Am2011-5361 |
0.323 |
|
| 2011 |
Xiang Y, Wood ER, Gancar J, Oguz U, Cubitt CL, Dalton WS, Shain KH, Koomen JM. Abstract 5112: Proteomic investigation of melphalan resistance in multiple myeloma to support selection of combination therapy Cancer Research. 71: 5112-5112. DOI: 10.1158/1538-7445.Am2011-5112 |
0.412 |
|
| 2011 |
Gebhard AW, Emmons MF, Argilagos RF, McLaughlin M, Koomen J, Cress AE, Hazlehurst LA. Abstract 3628: The forced interaction of α4 integrin and CD44 by the novel peptide HYD1 may be a determinant of HYD1-induced cell death in multiple myeloma Cancer Research. 71: 3628-3628. DOI: 10.1158/1538-7445.Am2011-3628 |
0.342 |
|
| 2011 |
Kim J, Fang B, Koomen J, Zhang G, Haura EB. Abstract 1629: A protein-protein interaction network for RalB-TBK1 signaling pathway in KRAS mutant non small cell lung cancer Cancer Research. 71: 1629-1629. DOI: 10.1158/1538-7445.Am2011-1629 |
0.437 |
|
| 2011 |
Zhang G, Chen A, Song L, Fu J, Kinose F, Bai Y, Fang B, Li J, Eschrich S, Koomen J, Haura E. Abstract 1627: Proteome-wide analysis of echinoderm microtubule associated protein like 4 – anaplastic lymphoma kinase (EML4-ALK) network in lung cancer Cancer Research. 71: 1627-1627. DOI: 10.1158/1538-7445.Am2011-1627 |
0.452 |
|
| 2010 |
Ren Y, Chen Z, Chen L, Fang B, Win-Piazza H, Haura E, Koomen JM, Wu J. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes & Cancer. 1: 994-1007. PMID 21442024 DOI: 10.1177/1947601910395582 |
0.371 |
|
| 2010 |
Machida K, Eschrich S, Li J, Bai Y, Koomen J, Mayer BJ, Haura EB. Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling Plos One. 5. PMID 20976048 DOI: 10.1371/Journal.Pone.0013470 |
0.407 |
|
| 2010 |
Chen Y, Gruidl M, Remily-Wood E, Liu RZ, Eschrich S, Lloyd M, Nasir A, Bui MM, Huang E, Shibata D, Yeatman T, Koomen JM. Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. Journal of Proteome Research. 9: 4215-27. PMID 20590165 DOI: 10.1021/Pr1005197 |
0.41 |
|
| 2010 |
Fang B, Haura EB, Smalley KS, Eschrich SA, Koomen JM. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. Biochemical Pharmacology. 80: 739-47. PMID 20361944 DOI: 10.1016/J.Bcp.2010.03.027 |
0.415 |
|
| 2010 |
Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, et al. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. Plos One. 5: e9646. PMID 20333297 DOI: 10.1371/Journal.Pone.0009646 |
0.349 |
|
| 2010 |
Thomas CE, Sexton W, Benson K, Sutphen R, Koomen J. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 953-9. PMID 20332277 DOI: 10.1158/1055-9965.Epi-10-0069 |
0.302 |
|
| 2010 |
Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer Nature Chemical Biology. 6: 291-299. PMID 20190765 DOI: 10.1038/Nchembio.332 |
0.414 |
|
| 2010 |
Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ. IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. The Journal of Biological Chemistry. 285: 3676-84. PMID 19940156 DOI: 10.1074/Jbc.M109.078212 |
0.347 |
|
| 2010 |
Turner JG, Dawson JL, Ciaravino EJ, Koomen JM, Sullivan DM. Abstract 725: Protein kinase-CK2 inhibition as a potential treatment for multiple myeloma Cancer Research. 70: 725-725. DOI: 10.1158/1538-7445.Am10-725 |
0.405 |
|
| 2010 |
Remily-Wood E, Benson K, Baz R, Chen A, Koomen J. Abstract 5557: Quantitative mass spectrometry assays for antibodies to measure multiple myeloma tumor burden and detect relapse Cancer Research. 70: 5557-5557. DOI: 10.1158/1538-7445.Am10-5557 |
0.369 |
|
| 2010 |
Eustace NJ, Fang B, Zhang G, Li J, Yoshida T, Koomen JM, Haura EB. Abstract A68: Assessing dose response to kinase inhibitors using quantitative mass spectrometry Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A68 |
0.455 |
|
| 2010 |
Aliancy J, Meads MB, Wood E, Chen Y, Koomen JM, Dalton WS, Shain KH. Abstract A67: An LC-MRM method to simultaneously measure abundance and activation of Src family tyrosine kinases in a B cell line model of IL-6 signaling Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A67 |
0.397 |
|
| 2010 |
Joseph BD, Fedorenko IV, Paraiso KHT, Fang B, Koomen JM, Smalley KSM. Abstract A66: Integrative phosphoproteomic analysis of signaling pathways in MMS-mutated melanoma Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A66 |
0.424 |
|
| 2010 |
Schramm KJ, Vibet S, Oguz U, Wojtkowiak J, Koomen JM, Gillies RJ. Abstract A65: Changes in protein expression related to acidosis in the tumor microenvironment Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A65 |
0.405 |
|
| 2009 |
Remily-Wood E, Dirscherl H, Koomen JM. Acid hydrolysis of proteins in matrix assisted laser desorption ionization matrices. Journal of the American Society For Mass Spectrometry. 20: 2106-15. PMID 19679491 DOI: 10.1016/J.Jasms.2009.07.007 |
0.352 |
|
| 2008 |
Lu D, Liu RZ, Izumi V, Fenstermacher D, Haura EB, Koomen J, Eschrich SA. IPEP: An in silico tool to examine proteolytic peptides for mass spectrometry Bioinformatics. 24: 2801-2802. PMID 18842605 DOI: 10.1093/Bioinformatics/Btn511 |
0.349 |
|
| 2008 |
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Molecular & Cellular Proteomics : McP. 7: 1780-94. PMID 18664563 DOI: 10.1074/Mcp.R800002-Mcp200 |
0.342 |
|
| 2007 |
Ohshiro K, Rosenthal DI, Koomen JM, Streckfus CF, Chambers M, Kobayashi R, El-Naggar AK. Pre-analytic saliva processing affect proteomic results and biomarker screening of head and neck squamous carcinoma. International Journal of Oncology. 30: 743-9. PMID 17273777 DOI: 10.3892/Ijo.30.3.743 |
0.346 |
|
| 2005 |
Coombes KR, Koomen JM, Baggerly KA, Morris JS, Kobayashi R. Understanding the characteristics of mass spectrometry data through the use of simulation. Cancer Informatics. 1: 41-52. PMID 19305631 DOI: 10.4137/Cin.S0 |
0.326 |
|
| 2005 |
Chu F, Koomen JM, Kobayashi R, O'Brian CA. Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics. Cancer Research. 65: 10478-85. PMID 16288040 DOI: 10.1158/0008-5472.Can-05-1989 |
0.413 |
|
| 2005 |
Yokoi K, Shih LCN, Kobayashi R, Koomen J, Hawke D, Li D, Hamilton SR, Abbruzzese JL, Coombes KR, Fidler IJ. Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer International Journal of Oncology. 27: 1361-1369. PMID 16211233 DOI: 10.3892/Ijo.27.5.1361 |
0.323 |
|
| 2005 |
Campos-Fernández CS, Schottel BL, Chifotides HT, Bera JK, Bacsa J, Koomen JM, Russell DH, Dunbar KR. Anion template effect on the self-assembly and interconversion of metallacyclophanes. Journal of the American Chemical Society. 127: 12909-23. PMID 16159285 DOI: 10.1021/Ja052108Q |
0.406 |
|
| 2005 |
Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, Kobayashi R. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. Journal of Proteome Research. 4: 972-81. PMID 15952745 DOI: 10.1021/Pr050046X |
0.341 |
|
| 2005 |
Koomen JM, Zhao H, Li D, Nasser W, Hawke DH, Abbruzzese JL, Baggerly KA, Kobayashi R. Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. Rapid Communications in Mass Spectrometry : Rcm. 19: 1624-36. PMID 15915451 DOI: 10.1002/Rcm.1963 |
0.389 |
|
| 2005 |
Koomen J, Hawke D, Kobayashi R. Developing an understanding of proteomics: An introduction to biological mass spectrometry Cancer Investigation. 23: 47-59. PMID 15779868 DOI: 10.1081/Cnv-46344 |
0.327 |
|
| 2005 |
Morris JS, Coombes KR, Koomen J, Baggerly KA, Kobayashi R. Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics (Oxford, England). 21: 1764-75. PMID 15673564 DOI: 10.1093/Bioinformatics/Bti254 |
0.308 |
|
| 2004 |
Koomen JM, Zhao H, Li D, Abbruzzese J, Baggerly K, Kobayashi R. Diagnostic protein discovery using proteolytic peptide targeting and identification. Rapid Communications in Mass Spectrometry : Rcm. 18: 2537-48. PMID 15468157 DOI: 10.1002/Rcm.1657 |
0.4 |
|
| 2004 |
Chifotides HT, Koomen JM, Kang M, Tichy SE, Dunbar KR, Russell DH. Binding of DNA purine sites to dirhodium compounds probed by mass spectrometry. Inorganic Chemistry. 43: 6177-87. PMID 15446862 DOI: 10.1021/Ic040040U |
0.429 |
|
| 2004 |
Woods AS, Ugarov M, Egan T, Koomen J, Gillig KJ, Fuhrer K, Gonin M, Schultz JA. Lipid/peptide/nucleotide separation with MALDI-ion mobility-TOF MS. Analytical Chemistry. 76: 2187-95. PMID 15080727 DOI: 10.1021/Ac035376K |
0.314 |
|
| 2003 |
Koomen JM, Lucas JE, Haneline MR, Beckwith King JD, Gabbai F, Russell DH. Nanoelectrospray MS and MS-MS investigation of two polydendate Lewis acids, (C6F4Hg)3 and o-C6F4(HgCl)2, characterization and halide binding selectivity International Journal of Mass Spectrometry. 225: 225-231. DOI: 10.1016/S1387-3806(02)01114-4 |
0.417 |
|
| 2002 |
Koomen JM, Ruotolo BT, Gillig KJ, McLean JA, Russell DH, Kang M, Dunbar KR, Fuhrer K, Gonin M, Schultz JA. Oligonucleotide analysis with MALDI-ion-mobility-TOFMS. Analytical and Bioanalytical Chemistry. 373: 612-7. PMID 12185573 DOI: 10.1007/S00216-002-1363-2 |
0.624 |
|
| 2002 |
Sulikowski GA, Agnelli F, Spencer P, Koomen JM, Russell DH. Studies on the biosynthesis of phomoidride B (CP-263,114): evidence for a decarboxylative homodimerization pathway. Organic Letters. 4: 1447-50. PMID 11975600 DOI: 10.1021/Ol025594K |
0.425 |
|
| 2002 |
Koomen JM, Russell WK, Tichy SE, Russell DH. Accurate mass measurement of DNA oligonucleotide ions using high-resolution time-of-flight mass spectrometry. Journal of Mass Spectrometry : Jms. 37: 357-71. PMID 11948842 DOI: 10.1002/Jms.312 |
0.478 |
|
| 2002 |
Woods AS, Koomen JM, Ruotolo BT, Gillig KJ, Russel DH, Fuhrer K, Gonin M, Egan TF, Schultz JA. A study of peptide-peptide interactions using MALDI ion mobility o-TOF and ESI mass spectrometry. Journal of the American Society For Mass Spectrometry. 13: 166-9. PMID 11838019 DOI: 10.1016/S1044-0305(01)00348-8 |
0.59 |
|
| 2002 |
Koomen JM, Kang M, Chifotides H, Dunbar KR, Russell DH. A comparison of MALDI and ESI for analysis of dirhodium-DNA adducts Proceedings 50th Asms Conference On Mass Spectrometry and Allied Topics. 429-430. |
0.352 |
|
| 2001 |
Campos-Fernández CS, Clérac R, Koomen JM, Russell DH, Dunbar KR. Fine-tuning the ring-size of metallacyclophanes: a rational approach to molecular pentagons. Journal of the American Chemical Society. 123: 773-4. PMID 11456607 DOI: 10.1021/Ja002960R |
0.399 |
|
| 2000 |
Koomen JM, Russell DH. Ultraviolet/matrix-assisted laser desorption/ionization mass spectrometric characterization of 2,5-dihydroxybenzoic acid-induced reductive hydrogenation of oligonucleotides on cytosine residues. Journal of Mass Spectrometry : Jms. 35: 1025-34. PMID 10973002 DOI: 10.1002/1096-9888(200008)35:8<1025::Aid-Jms30>3.0.Co;2-9 |
0.463 |
|
| 2000 |
Koomen JM, Russell WK, Hettick JM, Russell DH. Improvement of resolution, mass accuracy, and reproducibility in reflected mode DE-MALDI-TOF analysis of DNA using fast evaporation--overlayer sample preparations. Analytical Chemistry. 72: 3860-6. PMID 10959974 DOI: 10.1021/Ac0001941 |
0.687 |
|
| 2000 |
Botos I, Meyer E, Nguyen M, Swanson SM, Koomen JM, Russell DH, Meyer EF. The structure of an insect chymotrypsin. Journal of Molecular Biology. 298: 895-901. PMID 10801356 DOI: 10.1006/Jmbi.2000.3699 |
0.421 |
|
| 2000 |
Koomen JM, Stoeckli M, Caprioli RM. Mapping of surrogate markers of cellular components and structures using laser desorption/ionization mass spectrometry. Journal of Mass Spectrometry : Jms. 35: 258-64. PMID 10679989 DOI: 10.1002/(Sici)1096-9888(200002)35:2<258::Aid-Jms937>3.0.Co;2-Q |
0.312 |
|
| Show low-probability matches. |